Company / EPS (Diluted)
Myriad Genetics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.18
FY2025
5-year range
-$3.18 / $0.06
FY2021-FY2025
Trend
-128.8%
vs FY2024
Sector context
#148 of 204
Health Care
What the data says
At $-3.18, Myriad Genetics, Inc.'s eps (diluted) ranks #148 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-3.18 in FY2025 to $2.25 in FY2016.
Based on SEC 10-K filings.
-3.18 in FY2025.
Declined from $-0.35 to $-3.18 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#148 of 204 in Health CareTop 73% of 204This company -$3.18 Sector average -$0.98
▼
-224.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 128.8% year-over-year.
- Ranks #148 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.18 | -128.8% |
| FY2024 | -$1.39 | -297.1% |
| FY2023 | -$0.35 | +87.0% |
| FY2022 | -$2.69 | -4583.3% |
| FY2021 | $0.06 | -96.8% |
| FY2020 | $1.85 | +640.0% |
| FY2019 | $0.25 | -76.6% |
| FY2018 | $1.07 | -0.9% |
| FY2017 | $1.08 | -52.0% |
| FY2016 | $2.25 | +27.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026